Truist lowered the firm’s price target on Cigna (CI) to $375 from $405 but keeps a Buy rating on the shares. The firm remains bullish on Cigna folowing solid Q2 results marked by a stronger top-line, a bit better adjusted EPS and reaffirmed guidance, the analyst tells investors in a research note. Evernorth demand trends remain brisk, and selling season commentary was solid, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Cigna price target lowered to $365 from $375 at Oppenheimer
- Cigna’s Strong Growth Potential and Strategic Focus Drive Buy Rating
- Cigna’s Growth Potential Driven by Evernorth and Specialty Market Expansion
- Cigna price target lowered to $354 from $385 at Barclays
- Cigna Group Reports Strong Q2 2025 Earnings